.Pharmacolibrary.Drugs.ATC.A.A10BG03 .Pharmacolibrary.Drugs.ATC.A.A10BG03| name: | Pioglitazone |
| ATC code: | A10BG03 | route: | oral |
| n-compartments | 2 |
Pioglitazone is a thiazolidinedione antidiabetic drug used to improve glycemic control in adults with type 2 diabetes mellitus either as monotherapy or in combination with other antidiabetic agents. It acts as an agonist at peroxisome proliferator-activated receptor gamma (PPAR-γ), reducing insulin resistance. Pioglitazone is approved and in clinical use.
Pharmacokinetic parameters reported for healthy adult subjects after single oral dose administration.
Kirchheiner, J, et al., & Brockmöller, J (2005). Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clinical pharmacokinetics 44(12) 1209–1225. DOI:10.2165/00003088-200544120-00002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16372821
Terrones-Gurrola, MCDR, et al., & Vértiz-Hernández, AA (2023). Arsenic: A Perspective on Its Effect on Pioglitazone Bioavailability. International journal of environmental research and public health 20(3) –. DOI:10.3390/ijerph20031901 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36767268
Yin, SJ, et al., & Zhang, GL (2017). Effects of functional CYP2C8,CYP2C9,CYP3A5,and ABCB1 genetic variants on the pharmacokinetics of insulin sensitizer pioglitazone in Chinese Han individuals. Pharmacogenetics and genomics 27(4) 125–134. DOI:10.1097/FPC.0000000000000265 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28099407